ArticleNPJ precision oncology2026
CDNFE suggests FNDC3B and NECTIN4 as drivers of precancer progression via PI3K/AKT EMT.
Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
A tipping point signals the shift from a stable phase to a malignant state in cervical cancer progression. Identifying this transition is essential for early intervention, yet traditional biomarkers based on differential expression or undirected network measures often fail to capture it. Here, we introduce Causality-Directed Network Flow Entropy (CDNFE), a framework that quantifies entropy dynamics in directed regulatory networks to detect disease tipping points with superior sensitivity over expression-based methods. Applied to cervical cancer data which were derived from samples of different clinical stages collected from Luohe Central Hospital (single-cell, bulk transcriptome, simulations, and spatial transcriptomics), CDNFE consistently identified a precancerous tipping point and uncovered a biomarker module enriched for non-differentially expressed "dark genes." Within this module, FNDC3B and NECTIN4 emerged as central hubs, validated across multiple levels: (1) functionally essential in cervical cancer cell lines, (2) structurally important as driver nodes within regulatory networks, (3) mechanistically suggesting a potential link to PI3K/AKT signaling driven by epithelial-mesenchymal transition, and (4) spatially enriched in tumor regions in independent spatial transcriptomics sections. These findings establish CDNFE as a robust systems-level framework for tipping point detection and highlight FNDC3B and NECTIN4 as representative dark gene regulators of cervical cancer progression.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.